Cargando…

Microvesicles in CLL: predictor of disease progression/relapse

Detalles Bibliográficos
Autores principales:	Maiti, Guru P., Kay, Neil E., Ghosh, Asish K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710871/ https://www.ncbi.nlm.nih.gov/pubmed/29207590 http://dx.doi.org/10.18632/oncotarget.21868

Ejemplares similares

Dynamics of Microvesicle Generation in B Cell Chronic Lymphocytic Leukemia: Implication in Disease Progression
por: Boysen, Justin, et al.
Publicado: (2016)

SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis
por: Maiti, Guru P., et al.
Publicado: (2021)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Stem Cell-Released Microvesicles and Exosomes as Novel Biomarkers and Treatments of Diseases
por: Chen, Yanfang, et al.
Publicado: (2016)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)
por: Seymour, Erlene K.
Publicado: (2019)

Roles of Microvesicles in Tumor Progression and Clinical Applications
por: Zhu, Shuangli, et al.
Publicado: (2021)

Microvesicles and ectosomes in angiogenesis and diabetes - message in a bottle in the vascular ocean
por: Lichtenauer, Michael, et al.
Publicado: (2018)

Examining the role of microvesicles to develop prognostic and diagnostic assays
por: GHIRAN, Ionita, et al.
Publicado: (2010)

Loss of AID exacerbates the malignant progression of CLL
por: Lee, Avery C., et al.
Publicado: (2022)

Validating genomic tools for precision medicine in CLL: ERIC leads the way
por: Wiestner, Adrian
Publicado: (2021)

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016)

Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
por: Aldapt, Mahmood B, et al.
Publicado: (2021)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Platelet-Derived Microvesicles in Cardiovascular Diseases
por: Zaldivia, Maria T. K., et al.
Publicado: (2017)

Leukocyte Derived Microvesicles as Disease Progression Biomarkers in Slow Progressing Amyotrophic Lateral Sclerosis Patients
por: Sproviero, Daisy, et al.
Publicado: (2019)

Attack of the microvesicles
por: Wells, William A.
Publicado: (2002)

Microvesicles as a potential biomarker of neoplastic diseases and their role in development and progression of neoplasm
por: Kajdos, Magdalena, et al.
Publicado: (2015)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?
por: Whiteside, T L
Publicado: (2005)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Endothelial microvesicles in hypoxic hypoxia diseases
por: Deng, Fan, et al.
Publicado: (2018)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Simon, Florian, et al.
Publicado: (2023)

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
por: Thijssen, Rachel, et al.
Publicado: (2022)

Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry
por: Mato, Anthony R., et al.
Publicado: (2022)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

AID Contributes to Accelerated Disease Progression in the TCL1 Mouse Transplant Model for CLL
por: Schubert, Maria, et al.
Publicado: (2021)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
por: Reda, Gianluigi, et al.
Publicado: (2018)

The ins and outs of microvesicles
por: Clancy, James W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e1sb13cm9r3k8pfbc74s0p753c